Source Library — Primary Citations & References
TryTrutide cites primary sources wherever possible: FDA documents, peer-reviewed journals, ClinicalTrials.gov records, and official sponsor publications. This library organizes those sources by category for transparency and verification.
FDA & Regulatory Sources
Official database of FDA-approved drug applications, labeling, and approval letters.
FDA statement on unapproved GLP-1 products and enforcement concerns.
Current and resolved drug shortage listings relevant to compounding eligibility.
FDA guidance on 503A traditional compounding pharmacy requirements.
FDA guidance on 503B registered outsourcing facilities.
ClinicalTrials.gov Records
Live search of all registered retatrutide studies on the official US registry.
Phase 3 pivotal obesity trial — topline results announced May 21, 2026: 28.3% mean weight reduction at 80 weeks (12 mg).
Phase 3 trial in adults with obesity and type 2 diabetes — topline results announced July 23, 2026.
Phase 3 trial in adults with cardiovascular disease and severe obesity — topline results announced July 23, 2026.
Peer-Reviewed Publications
New England Journal of Medicine. Primary Phase 2 publication reporting up to 24.2% mean weight loss at 48 weeks with 12 mg retatrutide. The foundational peer-reviewed efficacy dataset.
PubMed / National Library of Medicine. Phase 1b study evaluating LY3437943 safety, tolerability, pharmacokinetics, and preliminary glycemic effects in people with type 2 diabetes.
Nature Medicine. Phase 2a substudy examining changes in liver fat content (MASLD) among retatrutide trial participants.
Cell Discovery (Nature Portfolio). Structural biology research examining how retatrutide interacts with GLP-1, GIP, and glucagon receptors at the molecular level.
International Journal of Obesity (Nature Portfolio). Scientific review discussing retatrutide within the developing anti-obesity medication pipeline.
Official Sponsor Publications
Official Eli Lilly overview of retatrutide (LY3437943) development, mechanism, and status. Manufacturer source.
Lilly's research and development pipeline page listing retatrutide (LY3437943) among investigational compounds and therapeutic areas under study.
Lilly investor-relations announcement of TRIUMPH-1 Phase 3 topline results, including 28.3% mean weight reduction at 80 weeks. Manufacturer press release.
Lilly announcement of positive topline results from TRIUMPH-2 and TRIUMPH-3. Manufacturer press release.
General Reference
General Reference / Secondary Source. Wikipedia's independently edited overview of retatrutide. Useful as a starting point; should be supplemented with peer-reviewed and primary sources for any clinical or research purpose. Not a primary scientific source.
Physical Activity & Nutrition
Federal physical activity recommendations for adults and special populations.
CDC summary of physical activity recommendations for adults.
CDC guidance on physical activity for healthy weight management.
Last reviewed: September 17, 2026